Allschwil, Switzerland, April 24, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial...
The FDA has approved Basilea Pharmaceutica’s advanced generation cephalosporin antibiotic, Zevtera (ceftobiprole medocaril), for the treatment of three major indications: Staphylococcus aureus bacteremia (SAB), including right-sided infective endocarditis, acute bacterial skin and skin structure infections (ABSSSI), and community-acquired bacterial pneumonia (CABP). As the first drug to reach the US market for the treatment of SAB in over 15 years, Zevtera will play a unique and critical role in the future management of this serious, and commonly fatal infection, says GlobalData.
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has been awarded a grant from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership dedicated to supporting the early development of antibacterial products. The grant award is to support initial preclinical activities on the antibiotics program recently acquired from Spexis. The initial funding of up to USD 0.9 million will support the work until candidate nomination in the second half of 2024. Basilea could receive additional funding from CARB-X, to continue preclinical and early clinical development of the antibiotics program, if the project achieves certain milestones.
FDA Approves New Antibiotic for Three Different Uses
Continued strong Cresemba sales performance in Asia Pacific
Increased Cresemba® and Zevtera®-related revenue of CHF 150.3 million (+22.9% year-on-year) at upper end of guidanceOperating profit of CHF 19.2 million and net profit of CHF 10.5 million,...
Cresemba sales in Latin America trigger first sales milestone payment to Basilea
Novel class of antibioticsBactericidal activity demonstrated in vitro and in vivo against broad range of Gram-negative bacteria, including multidrug-resistant strains Allschwil, Switzerland,...
Basilea provides portfolio status update
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, December 20, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to...